Roivant has decided to stop developing its drug namilumab for chronic active pulmonary sarcoidosis after it failed to show benefits in a mid-stage trial. Shares of the company dropped 4% after the announcement. The disease causes inflammatory cell lumps in the lungs and other organs leading to tissue damage and dysfunction. Current treatments only suppress symptoms. Roivant CEO expressed disappointment over the trial results, stating that science can be humbling. The American Lung Association reports 150,000 to 200,000 cases of sarcoidosis in the US annually. Another drug, efzofitimod by aTyr Pharma, is being tested for the same condition in late-stage development.
Source link
Roivant to Stop Lung Disease Drug Development After Trial Failure
